Sanofi SA vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Direxion Daily Semiconductor Bear 3X Shares trades at $45.66. The key difference: Sanofi SA pays a 5.5% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| SNY | SOXS | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $1.61K |
52-Week Low | $41.33 | $32.50 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $53.99, down 1.64% with a bearish moving average signal but bullish overall technical outlook. The ETF provides 3x leveraged inverse exposure to semiconductors, recently benefiting from sector volatility. A 1:10 stock split is scheduled for July 26, 2026, following a $0.04 dividend payment in June. Recent news highlights SOXS's surge during semiconductor sell-offs, with the ETF gaining attention as a tactical instrument amid AI-driven chip market fluctuations.
SOXS offers leveraged inverse exposure to semiconductor stocks, presenting high-risk, tactical opportunities during sector downturns. The bullish technical signal contrasts with overbought RSI readings, suggesting potential near-term volatility. Key risks include leverage decay, sector reversal momentum, and dependence on semiconductor market weakness. Investors should approach SOXS as a short-term hedging tool rather than a long-term holding due to its inverse structure and high volatility.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →